British journal of cancer · 1998

Results of a phase III, double-blind, placebo-controlled trial of megestrol acetate modulation of P-glycoprotein-mediated drug resistance in the first-line management of small-cell lung carcinoma.

Название и аннотация: Перевод в очереди

Обработка статьи · этапы, ошибки и управление

Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Wood L, Palmer M, Hewitt J, Urtasun R, Bruera E, Rapp E, Thaell JF

Аннотация

The objective of this study was to determine if the addition of megestrol acetate (MA), a modulator of P-glycoprotein-mediated drug resistance, to first-line cytotoxic therapy in patients with limited and advanced stage small-cell lung cancer (SCLC) would improve median time to disease progression and median overall survival. Secondary outcomes evaluated were response rates and patient symptom profile. Between 1992 and 1995, 130 eligible patients were randomized in a double-blind fashion to receive standard first-line therapy consisting of alternating courses of cyclophosphamide/doxorubicin/vincristine and etoposide/cisplatin (and thoracic radiotherapy for limited stage patients), along with either placebo or MA 160 mg t.i.d. for 8 days commencing 3 days before initiation of each cycle of chemotherapy. Treatment was continued for a maximum of six cycles. A total of 130 eligible patients were randomized, 65 to each arm. Fifty-two per cent of patients had limited disease and 48% had advanced disease. The median time to disease progression in limited stage disease was 46 weeks in the placebo arm and 43 weeks in the MA arm (P = 0.71) and in advanced stage disease was 28 weeks in the placebo arm and 27 weeks in the MA arm (P = 0.92). The median overall survival in limited stage disease was 75 weeks in the placebo arm and 75 weeks in the MA arm (P = 0.56) and in advanced stage disease was 41 weeks in the placebo arm and 39 weeks in the MA arm (P = 0.96). There was no consistent statistical difference in response rates or patient symptom profiles between the two treatment arms. The addition of MA, in the dose and schedule used, to standard first-line cytotoxic therapy in SCLC did not result in a significant improvement in response rates, symptom profile, median time to disease progression or overall survival.

Перевод полного текста: Перевод в очереди

Читать найденный полный текст

https://creativecommons.org/licenses/by/4.0/ This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/ .

Bellamy W. T. Dalton W. S. Multidrug resistance in the laboratory and clinic. 31 1994 1 61 Adv Clin Chem 7879670 10.1016/s0065-2423(08)60332-7

Bruera E. Macmillan K. Kuehn N. Hanson J. MacDonald R. N. A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer. 66 6 15 9 1990 1279 1282 Cancer 2205358 10.1002/1097-0142(19900915)66:6<1279::aid-cncr2820660630>3.0.co;2-r

Chin K. V. Pastan I. Gottesman M. M. Function and regulation of the human multidrug resistance gene. 60 1993 157 180 Adv Cancer Res 8417499 10.1016/s0065-230x(08)60825-8

Cole S. P. Bhardwaj G. Gerlach J. H. Mackie J. E. Grant C. E. Almquist K. C. Stewart A. J. Kurz E. U. Duncan A. M. Deeley R. G. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. 258 5088 4 12 1992 1650 1654 Science 1360704 10.1126/science.1360704

Cole S. P. Downes H. F. Slovak M. L. Effect of calcium antagonists on the chemosensitivity of two multidrug-resistant human tumour cell lines which do not overexpress P-glycoprotein. 59 1 1 1989 42 46 Br J Cancer PMC2246955 2569325 10.1038/bjc.1989.9

Cordon-Cardo C. O'Brien J. P. Boccia J. Casals D. Bertino J. R. Melamed M. R. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. 38 9 9 1990 1277 1287 J Histochem Cytochem 1974900 10.1177/38.9.1974900

Dalton W. S. Crowley J. J. Salmon S. S. Grogan T. M. Laufman L. R. Weiss G. R. Bonnet J. D. A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study. 75 3 1 2 1995 815 820 Cancer 7828131 10.1002/1097-0142(19950201)75:3<815::aid-cncr2820750311>3.0.co;2-r

Fleming G. F. Amato J. M. Agresti M. Safa A. R. Megestrol acetate reverses multidrug resistance and interacts with P-glycoprotein. 29 6 1992 445 449 Cancer Chemother Pharmacol 1348973 10.1007/BF00684845

Fogler W. E. Klinger M. R. Abraham K. G. Gottlinger H. G. Riethmuller G. Daddona P. E. Enhanced cytotoxicity against colon carcinoma by combinations of noncompeting monoclonal antibodies to the 17-1A antigen. 48 22 15 11 1988 6303 6308 Cancer Res 2460221

Fojo A. T. Ueda K. Slamon D. J. Poplack D. G. Gottesman M. M. Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. 84 1 1 1987 265 269 Proc Natl Acad Sci U S A PMC304184 2432605 10.1073/pnas.84.1.265

Goldstein L. J. Galski H. Fojo A. Willingham M. Lai S. L. Gazdar A. Pirker R. Green A. Crist W. Brodeur G. M. Expression of a multidrug resistance gene in human cancers. 81 2 18 1 1989 116 124 J Natl Cancer Inst 2562856 10.1093/jnci/81.2.116

Gottesman M. M. Pastan I. The multidrug transporter, a double-edged sword. 263 25 5 9 1988 12163 12166 J Biol Chem 2900833

Hopwood P. Stephens R. J. Machin D. Approaches to the analysis of quality of life data: experiences gained from a medical research council lung cancer working party palliative chemotherapy trial. 3 5 10 1994 339 352 Qual Life Res 7531054 10.1007/BF00451726

Lai S. L. Goldstein L. J. Gottesman M. M. Pastan I. Tsai C. M. Johnson B. E. Mulshine J. L. Ihde D. C. Kayser K. Gazdar A. F. MDR1 gene expression in lung cancer. 81 15 2 8 1989 1144 1150 J Natl Cancer Inst 2746668 10.1093/jnci/81.15.1144

Loprinzi C. L. Ellison N. M. Schaid D. J. Krook J. E. Athmann L. M. Dose A. M. Mailliard J. A. Johnson P. S. Ebbert L. P. Geeraerts L. H. Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. 82 13 4 7 1990 1127 1132 J Natl Cancer Inst 2193166 10.1093/jnci/82.13.1127

Millward M. J. Cantwell B. M. Munro N. C. Robinson A. Corris P. A. Harris A. L. Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomised study. 67 5 5 1993 1031 1035 Br J Cancer PMC1968472 8388231 10.1038/bjc.1993.189

Milroy R. A randomised clinical study of verapamil in addition to combination chemotherapy in small cell lung cancer. West of Scotland Lung Cancer Research Group, and the Aberdeen Oncology Group. 68 4 10 1993 813 818 Br J Cancer PMC1968611 8398713 10.1038/bjc.1993.433

Minato K. Kanzawa F. Nishio K. Nakagawa K. Fujiwara Y. Saijo N. Characterization of an etoposide-resistant human small-cell lung cancer cell line. 26 5 1990 313 317 Cancer Chemother Pharmacol 1976450 10.1007/BF02897284

Mirski S. E. Gerlach J. H. Cole S. P. Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin. 47 10 15 5 1987 2594 2598 Cancer Res 2436751

Reeve J. G. Rabbitts P. H. Twentyman P. R. Amplification and expression of mdr1 gene in a multidrug resistant variant of small cell lung cancer cell line NCI-H69. 60 3 9 1989 339 342 Br J Cancer PMC2247176 2571355 10.1038/bjc.1989.282

Rowland K. M. Jr Loprinzi C. L. Shaw E. G. Maksymiuk A. W. Kuross S. A. Jung S. H. Kugler J. W. Tschetter L. K. Ghosh C. Schaefer P. L. Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive-stage small-cell lung cancer: a North Central Cancer Treatment Group study. 14 1 1 1996 135 141 J Clin Oncol 8558188 10.1200/JCO.1996.14.1.135

Tchekmedyian N. S. Tait N. Moody M. Aisner J. High-dose megestrol acetate. A possible treatment for cachexia. 257 9 6 3 1987 1195 1198 JAMA 3806918

Twentyman P. R. Fox N. E. White D. J. Cyclosporin A and its analogues as modifiers of adriamycin and vincristine resistance in a multi-drug resistant human lung cancer cell line. 56 1 7 1987 55 57 Br J Cancer PMC2001675 3040060 10.1038/bjc.1987.153

Wishart G. C. Bissett D. Paul J. Jodrell D. Harnett A. Habeshaw T. Kerr D. J. Macham M. A. Soukop M. Leonard R. C. Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial. 12 9 9 1994 1771 1777 J Clin Oncol 8083699 10.1200/JCO.1994.12.9.1771

de Jong S. Zijlstra J. G. de Vries E. G. Mulder N. H. Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line. 50 2 15 1 1990 304 309 Cancer Res 1967222

Results of a phase III, double-blind, placebo-controlled trial of megestrol acetate modulation of P-glycoprotein-mediated drug resistance in the first-line management of small-cell lung carcinoma.

Ошибки и ограничения

Аннотация